Literature DB >> 30442328

Using Light to Endow Stem-Cell-Derived Cardiomyocytes With Virtual IK1 Conductances.

Teun P de Boer1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30442328      PMCID： PMC6289092          DOI： 10.1016/j.bpj.2018.10.019

Source DB:  PubMed          Journal:  Biophys J        ISSN： 0006-3495            Impact factor:   4.033


× No keyword cloud information.
  10 in total

1.  IK1-enhanced human-induced pluripotent stem cell-derived cardiomyocytes: an improved cardiomyocyte model to investigate inherited arrhythmia syndromes.

Authors:  Ravi Vaidyanathan; Yogananda S Markandeya; Timothy J Kamp; Jonathan C Makielski; Craig T January; Lee L Eckhardt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-08       Impact factor: 4.733

2.  Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.

Authors:  Min Li; Yasunari Kanda; Takashi Ashihara; Tetsuo Sasano; Yuji Nakai; Masami Kodama; Erina Hayashi; Yuko Sekino; Tetsushi Furukawa; Junko Kurokawa
Journal:  J Pharmacol Sci       Date:  2017-05-27       Impact factor: 3.337

3.  Light-Activated Dynamic Clamp Using iPSC-Derived Cardiomyocytes.

Authors:  Bonnie Quach; Trine Krogh-Madsen; Emilia Entcheva; David J Christini
Journal:  Biophys J       Date:  2018-10-30       Impact factor: 4.033

4.  Electronic "expression" of the inward rectifier in cardiocytes derived from human-induced pluripotent stem cells.

Authors:  Glenna C L Bett; Aaron D Kaplan; Agnieszka Lis; Thomas R Cimato; Emmanuel S Tzanakakis; Qinlian Zhou; Michael J Morales; Randall L Rasmusson
Journal:  Heart Rhythm       Date:  2013-09-19       Impact factor: 6.343

Review 5.  The immature electrophysiological phenotype of iPSC-CMs still hampers in vitro drug screening: Special focus on IK1.

Authors:  Birgit Goversen; Marcel A G van der Heyden; Toon A B van Veen; Teun P de Boer
Journal:  Pharmacol Ther       Date:  2017-10-03       Impact factor: 12.310

6.  Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.

Authors:  Ksenia Blinova; Jayna Stohlman; Jose Vicente; Dulciana Chan; Lars Johannesen; Maria P Hortigon-Vinagre; Victor Zamora; Godfrey Smith; William J Crumb; Li Pang; Beverly Lyn-Cook; James Ross; Mathew Brock; Stacie Chvatal; Daniel Millard; Loriano Galeotti; Norman Stockbridge; David G Strauss
Journal:  Toxicol Sci       Date:  2016-10-03       Impact factor: 4.849

7.  Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.

Authors:  Malin K B Jonsson; Marc A Vos; Gary R Mirams; Göran Duker; Peter Sartipy; Teun P de Boer; Toon A B van Veen
Journal:  J Mol Cell Cardiol       Date:  2012-02-14       Impact factor: 5.000

8.  A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.

Authors:  Hiroyuki Ando; Takashi Yoshinaga; Wataru Yamamoto; Keiichi Asakura; Takaaki Uda; Tomohiko Taniguchi; Atsuko Ojima; Raku Shinkyo; Kiyomi Kikuchi; Tomoharu Osada; Seiji Hayashi; Chieko Kasai; Norimasa Miyamoto; Hiroyuki Tashibu; Daiju Yamazaki; Atsushi Sugiyama; Yasunari Kanda; Kohei Sawada; Yuko Sekino
Journal:  J Pharmacol Toxicol Methods       Date:  2016-12-10       Impact factor: 1.950

9.  Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1.

Authors:  Rosalie M E Meijer van Putten; Isabella Mengarelli; Kaomei Guan; Jan G Zegers; Antoni C G van Ginneken; Arie O Verkerk; Ronald Wilders
Journal:  Front Physiol       Date:  2015-02-03       Impact factor: 4.566

10.  A Hybrid Model for Safety Pharmacology on an Automated Patch Clamp Platform: Using Dynamic Clamp to Join iPSC-Derived Cardiomyocytes and Simulations of Ik1 Ion Channels in Real-Time.

Authors:  Birgit Goversen; Nadine Becker; Sonja Stoelzle-Feix; Alison Obergrussberger; Marc A Vos; Toon A B van Veen; Niels Fertig; Teun P de Boer
Journal:  Front Physiol       Date:  2018-01-19       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.